newsfilter
← Latest News
PR Newswire·

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. VANCOUVER, BC, July 27, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE:MCUR) (OTCQB:MCU